Nakajima, Tomoya http://orcid.org/0000-0003-4211-034X
Watanabe, Ryu http://orcid.org/0000-0002-1089-5296
Hashimoto, Motomu http://orcid.org/0000-0002-9241-060X
Murata, Koichi http://orcid.org/0000-0002-7896-3937
Murakami, Kosaku http://orcid.org/0000-0001-5981-4648
Tanaka, Masao http://orcid.org/0000-0002-8942-2933
Ito, Hiromu http://orcid.org/0000-0002-1827-382X
Yamamoto, Wataru http://orcid.org/0000-0002-0810-4221
Kitagori, Koji http://orcid.org/0000-0001-8056-8648
Akizuki, Shuji
Nakashima, Ran http://orcid.org/0000-0001-6247-0647
Yoshifuji, Hajime http://orcid.org/0000-0001-7082-4900
Ohmura, Koichiro http://orcid.org/0000-0003-2927-9159
Matsuda, Shuichi http://orcid.org/0000-0003-0802-1255
Morinobu, Akio http://orcid.org/0000-0002-4672-638X
Funding for this research was provided by:
JSPS KAKENHI (20K17418)
Article History
Received: 15 March 2021
Accepted: 2 July 2021
First Online: 9 July 2021
Declarations
:
: The Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, AYUMI Pharmaceutical Co., and Asahi Kasei Pharma Corp.). The KURAMA cohort is also supported by grant from Daiichi Sankyo Co. Ltd. The above-mentioned pharmaceutical companies were not involved in the study design, data collection and analysis, manuscript writing, and manuscript submission. RW received speaker fees from Mitsubishi Tanabe Pharma, Pfizer, Sanofi, AbbVie, Asahi Kasei, Eisai, Eli Lilly, Bristol-Myers Squibb, and Janssen. MH received a research grant and/or speaker fees from Bristol-Myers, Eisai, Ely Lilly, Mitsubishi Tanabe Pharma, Novartis Pharma. KMurat received a speaking fee from Eisai Co., Ltd. and Astellas Pharma Inc. KMurak has received speaking fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co. Ltd, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc.. MT received research grants and/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Daiichi Sankyo Co. Ltd., Celgene Corp., Takeda Pharmaceutical Company Ltd., and Taisho Pharma Co., Ltd.. HI has received a research grant from Bristol-Myers Squibb, Asahi Kasei Pharma Corporation, Eisai, Mochida and Taisho. KK received research grants from GSK. RN has received research grants from Takeda and Medical & Biological Laboratories Co., Ltd. and speaking fees from Bristol-Myers Squibb, Astellas Pharma, Boehringer Ingelheim, Actelion Pharmaceuticals and Mitsubishi Tanabe Pharma, outside the submitted work. HY received lecture fees from Chugai and has been on the advisory board for a clinical trial conducted by Janssen. KO received research grants and/or speaker fees from AbbVie, Actelion Pharmaceuticals, Asahi Kasei Pharma, Astellas Pharma, Ayumi Pharmaceutical, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly, GSK, JB, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Nippon Shinyaku, Mitsubishi Tanabe Pharma, Novartis Pharma, Sanofi, Takeda Pharmaceutical. SM has received a research grant and/or speaker fee from Kyocera Medical Co., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, Eisai Co., Ltd., Pfizer, Eli Lilly, Taisho Pharma Co., Ltd., and Ono Pharmaceutical Co.. AM has received research grants from AbbVie, Asahi Kasei Pharma, Chugai Pharmaceutical, Ono Pharmaceutical and speaking fees from Eli Lilly, AbbVie, Ono Pharmaceutical, Pfizer, Astellas Pharmaceutical, Chugai Pharmaceutical. All other authors have declared no conflicts of interest.
: The study protocol was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (No. R0357).
: Written informed consent to participate in the KURAMA cohort was obtained from all patients.
: Written informed consent to publish the study results was obtained from all patients.